In this lab experiment, scientists looked at how the drug semaglutide affects muscle cells that have been made resistant to insulin, similar to what happens in type 2 diabetes
Obesity in Adults: Drug Therapy. Edited by F Xavier Pi-Sunyer and Sara Swenson, UpToDate, Wolters Kluwer, 21 Dec
The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
Across military communities, the message has been reduced to a headline that says these drugs are finally covered
Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Their Cardiovascular BenefitsThe Role of the GLP-1 Receptor
Furthermore, semaglutide treatment led to an increase in mitochondrial content and density, as well as an increase in maximal mitochondrial respiration
